Gilead agreed to acquire a Phase 1 oral IL-23 receptor inhibitor program from PepStar Therapeutics, with the deal valued at $1.275 billion upfront for worldwide rights to HCXT-2001. The IL-23R target is already validated across immune-mediated inflammatory diseases, and Gilead is positioning the asset as a potentially differentiated oral route for daily treatment. The acquisition underscores Gilead’s broader inflammation and immunology buildout, pairing platform-appropriate modalities with late-stage commercial intent for oral peptides. Company statements framed the asset for use alone or in combination, including potential pairing with existing therapies. Separately, EQT agreed to take Qiagen private in a €10.8 billion ($12.1 billion) cash deal, reflecting continued consolidation in diagnostics and life-sciences tools. For biotech, tooling and workflows are strategic inputs to discovery and development cycles, and private ownership can influence long-term investment priorities and product roadmaps.